BioSpace News Archive

Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported third quarter 2021 financial results and highlighted recent achievements and developments.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced financial results for the third quarter ended September 30, 2021 and highlighted recent corporate developments.

CareDx, Inc. today announced key data and presentations at the American Society of Nephrology (ASN) Kidney Week 2021, which will be held virtually from November 4-7, 2021.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

Bio-Techne Corporation announced the commercial availability of GMP-grade materials manufactured at its St. Paul, MN GMP manufacturing facility.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced its operational and financial results for the third quarter ended September 30, 2021.

Insightec announced today that the U.S. Food and Drug Administration (FDA) has approved the Exablate® Neuro for treating advanced Parkinson’s Disease patients suffering from mobility, rigidity, or dyskinesia symptoms.

Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place Nov. 10-14, 2021

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the three and nine months ended September 30, 2021 and recent business achievements.

Precision BioSciences, Inc. today announced that it will publish financial results for the third quarter 2021 and provide a business update on November 10, 2021.